KAM
UTHR icon

Knightsbridge Asset Management’s United Therapeutics UTHR Stock Holding History

Knightsbridge Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Sell
392
-28
-7% -$15.8K 0.03% 282
2026
Q1 		$249K Sell
420
-4
-0.9% -$1.99K 0.03% 217
2025
Q4 		$207K Buy
+424
New +$197K 0.03% 214

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Knightsbridge Asset Management's UTHR Position: Q2 2026 in Review

Knightsbridge Asset Management reduced its United Therapeutics (UTHR) stake by 6.7% in Q2 2026, selling an estimated $15.8K and leaving 392 shares worth $212K. The position accounts for 0.03% of the portfolio, ranked #282.

Knightsbridge Asset Management first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $249K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Knightsbridge Asset Management held 392 shares of United Therapeutics worth $212K as of Q2 2026.
  • Knightsbridge Asset Management sold 28 United Therapeutics shares in Q2 2026, an estimated $15.8K.
  • United Therapeutics made up 0.03% of Knightsbridge Asset Management's portfolio in Q2 2026, its #282 holding.
  • Knightsbridge Asset Management first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Knightsbridge Asset Management's United Therapeutics position peaked at $249K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Knightsbridge Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.